Immunology and Bi...
Follow
Find
7.8K views | +4 today
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Manufacturing Methods for Cell Therapies | GEN Magazine Articles | GEN

Invetech discusses how equipment and processing considerations for allogenic therapeutics differ from those for autologous therapeutics.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stellar Biotechnologies Presents Poster at Immunology 2015 on the ... - CNNMoney

Stellar Biotechnologies Presents Poster at Immunology 2015 on the ... - CNNMoney | Immunology and Biotherapies | Scoop.it
Stellar Biotechnologies Presents Poster at Immunology 2015 on the ...
Gilbert Faure au nom de l'ASSIM's insight:

KLH still alive

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Pamlico BioPharma Human Monoclonal Antibodies

Pamlico BioPharma Human Monoclonal Antibodies | Immunology and Biotherapies | Scoop.it

Pamlico Biopharma, Inc. was founded around human monoclonal antibody therapeutics and technologies from the OMRF and from Emory University. PAMLICO focuses on human monoclonal antibody therapeutics for human pathogens, cancer and autoimmune diseases. The lead project will address pneumonia caused by S pneumoniae. Pneumococcal pneumonia remains a major cause of morbidity and mortality worldwide. The magnitude of the clinical challenge is likely to increase as multiple strains of the bacteria have developed resistance to multiple antibiotics. PAMLICO’s lead project is a monoclonal antibody therapy for severe (PSI -V) community-acquired pneumonococcal pneumonia, which has a 20-35% mortality rate that has remained constant for 2 decades. The therapeutic goal is to reduce mortality by 20%, which the company anticipates demonstrating in a superiority study compared to standard care alone.


Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

human monoclonals on this topic

http://www.scoop.it/t/immunology-and-biotherapies?q=human+monoclonal

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Rheumatologists Urged: Know Your Biosimilars - MedPage Today

Rheumatologists Urged: Know Your Biosimilars - MedPage Today | Immunology and Biotherapies | Scoop.it
Involving patient in the treatment decision should also be a consideration.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody | Immunology and Biotherapies | Scoop.it
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. . .

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 27, 10:21 AM
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody PreviewView full textDownload full textSupplementalAccess optionsDOI:10.1080/19420862.2015.1032491Sanjaya Singha*, Rachel R. Kroe-Barretta, Keith A. Canadaa, Xiang Zhua, Eliud Sepulvedaa, Helen Wua, Yaqin Hea, Ernest L Raymondb, Jennifer Ahlberga, Lee E. Fregoa, Laura M Amodeoa, Katrina M Catrona, David H. Preskya & Jeffrey H. Hankec Publishing models and article dates explainedReceived: 20 Jan 2015Accepted: 18 Mar 2015
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice

Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice | Immunology and Biotherapies | Scoop.it
Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice http://t.co/QPf5GqdpK1
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Meditope Biosciences

Meditope Biosciences | Immunology and Biotherapies | Scoop.it

PASADENA, Calif., April 20, 2015 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-based products using its proprietary technology, today announced presentation of data demonstrating the use of its SnAP technology platform for the development of antibody-drug conjugates (ADCs). The data were presented in an abstract at the AACR Annual Meeting 2015, taking place April 18-22 in Philadelphia.

 

Scientists at the company demonstrated the successful transplantation of the meditope binding site to several antibodies. Meditope-peptides of different affinities were then selected by rational design and fine-tuned according to the requirements of specific application. For ADC development, data show that the meditope-peptides are conjugated with cytotoxic payloads and the higher the affinity of the meditope-peptide-drug conjugate for the antibody, the higher the complex's cytotoxic potential against antigen-positive tumor cells.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 21, 7:56 AM

Meditope Biosciences' SnAP - Site-specific, novel Antibody Platform—technology is carving a new space in antibody design by turning antibodies into a "Lego-like" piece that can be combined with other pieces to expand functionality by easily 'snapping' anything imaginable on to (or off of) an antibody.

Scooped by Gilbert Faure au nom de l'ASSIM from Melanoma BRAF Inhibitors Review
Scoop.it!

Therapeutic Advances and Treatment Options in Metastatic Melanoma

Therapeutic Advances and Treatment Options in Metastatic Melanoma | Immunology and Biotherapies | Scoop.it
This review discusses the development of targeted and immune therapies for advanced melanoma, reviews current patient management, and highlights future directions.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 25, 3:37 AM
Review | April 23, 2015Therapeutic Advances and Treatment Options in Metastatic Melanoma FREE ONLINE FIRSTDouglas B. Johnson, MD, MSCI1,2; Jeffrey A. Sosman, MD1,2[+] Author AffiliationsJAMA Oncol. Published online April 23, 2015. doi:10.1001/jamaoncol.2015.0565
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases, Immunotherapy, Future Medicine

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases, Immunotherapy, Future Medicine | Immunology and Biotherapies | Scoop.it
Progress monoclonal antibody #biosimilars development: #infliximab #biosimilar CT-P13 in treatment rheumatic diseases
http://t.co/JlBWYQ61Nd
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

T-cell therapy sends young cancer patients into remission

T-cell therapy sends young cancer patients into remission | Immunology and Biotherapies | Scoop.it
More than 90 percent of children and young adults with acute lymphoblastic leukemia, or ALL, are in remission after treatment as part of a promising Seattle Children’s clinical trial, researchers reported.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Novel approach allows real-time imaging of ongoing immune response

Novel approach allows real-time imaging of ongoing immune response | Immunology and Biotherapies | Scoop.it
A novel approach that allows real-time imaging of the immune system's response to the presence of tumors—without the need for blood draws or invasive biopsies—offers a potential breakthrough both in diagnostics and in the ability to monitor...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Opinion: Predicting the Efficacy of Cancer Immunotherapy - The Scientist (press release) (registration)

Opinion: Predicting the Efficacy of Cancer Immunotherapy - The Scientist (press release) (registration) | Immunology and Biotherapies | Scoop.it
T-cell receptor repertoires could help researchers determine whether a certain treatment will work for a given cancer patient. 
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Breakthrough development in cancer immunology published in Nature

Breakthrough development in cancer immunology published in Nature | Immunology and Biotherapies | Scoop.it
BioNTech AG announced the publication of a scientific article on therapeutic immune responses to cancer in the internationally renowned scientific journal Nature.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Biologics: China's new wave of innovation

Biologics: China's new wave of innovation | Immunology and Biotherapies | Scoop.it
Founders and senior executives from four of China's most innovative biologics companies will discuss where biologics innovation stands now and how it is evolving in the future.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Hepatitis C New Drugs Review
Scoop.it!

A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity

A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity | Immunology and Biotherapies | Scoop.it
We describe the production and characterization of human monoclonal antibodies (mAb) specific for the major hepatitis B virus (HBV) S protein.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 30, 7:57 AM

Citation: Cerino A, Bremer CM, Glebe D, Mondelli MU (2015) A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity. PLoS ONE 10(4): e0125704. doi:10.1371/journal.pone.0125704

Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Cancer vaccines. BMJ

Cancer vaccines. BMJ | Immunology and Biotherapies | Scoop.it

Abstract

Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are specific to tumor antigens. The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been shown to be immunogenic and capable of inducing clinical responses in a minority of people with late stage cancer. Technological developments in the past few years have enabled the investigation of vaccines that target mutated antigens that are patient specific. Several platforms for cancer vaccination are being tested, including peptides, proteins, antigen presenting cells, tumor cells, and viral vectors. Standard of care treatments, such as surgery and ablation, chemotherapy, and radiotherapy, can also induce antitumor immunity, thereby having cancer vaccine effects. The monitoring of patients’ immune responses at baseline and after standard of care treatment is shedding light on immune biomarkers. Combination therapies are being tested in clinical trials and are likely to be the best approach to improving patient outcomes.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 30, 12:42 AM

Clinical Review   

State of the Art Review

Cancer vaccines

BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h988 (Published 22 April 2015)Cite this as: BMJ 2015;350:h988

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia | Life-Sciences

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia | Life-Sciences | Immunology and Biotherapies | Scoop.it
New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia http://t.co/bkFi7uecXA
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Immuno-Oncology - Merck Serono

Immuno-Oncology - Merck Serono | Immunology and Biotherapies | Scoop.it
PipelineThe current immuno-oncology portfolio comprises therapeutic candidates in early clinical development and a pipeline of preclinical molecules. Lead investigational candidates in clinical development include:avelumab** (MSB0010718C) 
Avelumab (also known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and could induce antibody-dependent cell-mediated cytotoxicity (ADCC).**avelumab = proposed International Non-proprietary Name (INN), formerly referred to as Anti-PD-L1 mAb (MSB0010718C)NHS-IL12 
NHS-IL12 (also known as MSB0010360) is an investigational cancer immunotherapy (immunocytokine) that is designed to target interleukin-12 to necrotic regions found in solid tumors. 

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Findings suggest development of 'post-infection' vaccine to reduce TB rates in ... - News-Medical.net

Findings suggest development of 'post-infection' vaccine to reduce TB rates in ... - News-Medical.net | Immunology and Biotherapies | Scoop.it
A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

GEN | Insight & Intelligence™:AACR Special: Serial Killer Cells on the Side of the Angels

GEN | Insight & Intelligence™:AACR Special: Serial Killer Cells on the Side of the Angels | Immunology and Biotherapies | Scoop.it
At the annual meeting of the American Association of Cancer Researchers, presenters discuss strategies to improve the safety and effectiveness of reengineered T cells in eradicating tumors.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 23, 1:58 AM

CAR T Cell immunotherapy, TIL, ATC, TCR   unpredictable toxicity at AACR 2015

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

HIV Immunotherapy Promising in First Human Study - NIH Research Matters - National Institutes of Health (NIH)

HIV Immunotherapy Promising in First Human Study - NIH Research Matters - National Institutes of Health (NIH) | Immunology and Biotherapies | Scoop.it
An experimental antibody significantly reduced HIV levels in infected people for as long as 28 days. The approach might help to combat a wide range of HIV strains.

 

In the current study, the researchers evaluated one of these promising monoclonal anti-HIV antibodies in people. The small phase 1 clinical trial included 29 volunteers—17 HIV-infected and 12 uninfected. The study was supported by the Bill and Melinda Gates Foundation, NIH’s National Institute of Allergy and Infectious Diseases (NIAID), and others. Results appeared online on April 8, 2015, in Nature.

 

The participants received a single intravenous dose (of 1, 3, 10, or 30 milligrams per kilogram of body weight) of the experimental antibody called 3BNC117. The antibody was well-tolerated by all participants. Among those infected with HIV, the 2 lower doses caused small and transient changes in blood HIV levels. The 8 participants who received the highest dose, however, had significant and rapid decreases in HIV. The virus’s resistance to the antibody was variable. In some people, HIV remained sensitive to 3BNC117 for 28 days.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 25, 3:20 AM

NIH  

 

 Dr. Michel C. Nussenzweig of the Howard Hughes Medical Institute at Rockefeller University 

 

At a GlanceA single infusion of an experimental antibody significantly reduced HIV levels in infected people for as long as 28 days.This and similar antibodies might help to combat a wide range of HIV strains.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer

Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer | Immunology and Biotherapies | Scoop.it
"Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer [EDITORIALS]" JCO http://t.co/scQQMzSmF6
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Adaptimmune - engineered, increased affinity T cell receptors

Adaptimmune - engineered, increased affinity T cell receptors | Immunology and Biotherapies | Scoop.it
Adaptimmune - increased affinity T cell receptors . Adaptimmune is focused on T cells to target and destroy cancer by using increased affinity TCRs .
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute ... - Nature.com

Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute ...
Nature.com
The anti-CD25 monoclonal antibody (mAb) is one of the most used second-line treatment choices for steroid-refractory aGVHD.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests - Springer

Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests - Springer | Immunology and Biotherapies | Scoop.it
Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests #mAbs #biosimilars #LC
http://t.co/7liwH8lPP0
more...
No comment yet.